马来酸曲美布汀治疗胃食管反流病患者临床疗效观察及对患者食管运动功能的影响

目的：探讨马来酸曲美布汀治疗胃食管反流病患者临床疗效观察及对患者食管运动功能的影响。方法：选自我院于2015年4月~2016年4月期间收治的胃食管反流病患者92例,按照随机数字表法随机分为观察组46例与对照组46例。对照组口服奥美拉唑肠溶片,观察组再对照组基础上结合马来酸曲美布汀。两组均以4周为1疗程,连续观察2个疗程。比较两组患者治疗疗效,治疗前后CCK、MTL水平变化,治疗前后临床发作频率及症状程度积分,治疗前后 LESP及LES松弛率变化,及不良反应发生情况。结果：观察组治疗总有效率(91.30%)高于对照组(73.91%)(P<0.05)；两组治疗后血清CCK水平增加,而MTL水平下降(P<0.05)；观察组治疗后血清CCK水平高于对照组,而MTL水平低于对照组(P<0.05)；两组治疗后临床发作频率及症状程度积分降低(P<0.05)；观察组治疗后临床发作频率及症状程度积分低于对照组(P<0.05)；两组治疗后LESP及LES松弛率增加(P<0.05)；观察组治疗后LESP及LES松弛率高于对照组(P<0.05)；两组均未见严重不良反应。结论：马来酸曲美布汀治疗胃食管反流病患者临床疗效显著,且可改善患者食管运动功能。

Trimebutine maleate in the treatment of gastroesophageal reflux disease in patients with clinical efficacy and effect on esophageal motor function in patients

Objective: To investigate the effects of trimebutine maleate in the treatment of gastroesophageal reflux disease in patients with clinical efficacy and effect on esophageal motor function in patients. Methods: 92 cases of gastroesophageal reflux disease admitted in our hospital from April 2015 to April 2016 were randomly divided into observation group 46 cases and control group 46 cases. Control group was treated with Omeprazole Enteric-coated Tablets, the observation group and the control group based on the combination of trimebutine maleate. The two groups were 4 weeks for 1 courses of treatment, continuous observation of 2 courses. Comparison of two groups of patients with treatment efficacy, before and after treatment, MTL, CCK level changes before and after treatment, clinical frequency and symptom scores, LESP and LES relaxation rate changes before and after treatment, and adverse reactions occurred. Results: the total efficiency of the observation group (91.30%) was higher than the control group (73.91%) (P<0.05); increase the serum level of CCK in two groups after treatment, and decreased MTL level (P<0.05); serum CCK levels after treatment in the observation group than the control group, while the level of MTL was lower than that of the control group (P<0.05); the two groups after treatment the seizure frequency and severity score decreased (P<0.05); clinical observation group after treatment and the degree of symptom integral frequency is lower than the control group (P<0.05); the two groups after the treatment of LESP and LES relaxation rate increased (P<0.05); the observation group after the treatment of LESP and LES relaxation rate was higher than the control group (P<0.05); serious adverse reactions of the two groups. Conclusion: trimebutine maleate in the treatment of gastroesophageal reflux disease in patients with significant clinical effect, and can improve the motor function of patients with esophageal.